Tacoma, WA 的 乳癌 臨床試驗
18 項針對 乳癌 的研究正在 Tacoma（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Vanguard Study: Testing a New Way to Screen for Cancer
招募中歡迎健康志工
- Madigan Army Medical Center, Tacoma
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
招募中3 期
- Northwest Medical Specialties, Tacoma
- Providence Regional Cancer System, Lacey · 距離 23 英里
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Providence Regional Cancer System-Lacey, Lacey · 距離 23 英里
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
招募中3 期
- Research Site, Puyallup · 距離 8 英里
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
招募中2 期
- Northwest Medical Specialties, Puyallup · 距離 8 英里
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
招募中3 期
- Northwest Medical Specialties, PLLC ( Site 0062), Tacoma
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
招募中3 期
- Research Site, Tacoma
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
招募中3 期
- Northwest Medical Specialties, Tacoma
- Northwest Medical Specialties, Gig Harbor · 距離 8 英里
- Northwest Medical Specialties, Puyallup · 距離 8 英里
- 還有 1 項
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
招募中3 期
- Northwest Medical Specialties, PLLC ( Site 0067), Tacoma
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
招募中
- MultiCare Cancer Institute, Tacoma
- Northwest Medical Specialties, PLLC, Puyallup · 距離 8 英里
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
招募中3 期
- Clinical Trial Site, Olympia · 距離 26 英里
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
招募中3 期
- MultiCare Health System, Tacoma
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
招募中3 期
- Northwest Medical Specialties, PLLC, Tacoma
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
招募中3 期
- MultiCare Cancer Institute - Tacoma, Tacoma
- Northwest Medical Specialties PLLC, Tacoma
- Vista Oncology, Olympia · 距離 26 英里
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
招募中3 期
- Northwest Medical Specialties, Tacoma
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
招募中3 期
- Providence Regional Cancer System-Lacey, Lacey · 距離 23 英里
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
招募中1/2 期
- Northwest Medical Specialties, PLLC, Tacoma
BostonGene and Exigent Genomic INsight Study
招募中觀察性研究
- Northwest Medical Specialities, Puyallup · 距離 8 英里
其他城市的 乳癌 試驗
- New York City, NY136 項研究
- Houston, TX126 項研究
- Boston, MA112 項研究
- Nashville, TN81 項研究
- Los Angeles, CA73 項研究
- Edison, NJ68 項研究
- St. Louis, MO64 項研究
- Queens, NY64 項研究
- Durham, NC64 項研究
- Chicago, IL59 項研究
- Philadelphia, PA56 項研究
- Dallas, TX55 項研究
Tacoma 的其他研究
- 非小細胞肺癌20 項研究
- 潰瘍性結腸炎15 項研究
- 多發性骨髓瘤13 項研究
- 前列腺癌11 項研究
- 克隆氏症11 項研究
- 大腸直腸癌9 項研究
- 轉移性癌症9 項研究
- 黑色素瘤7 項研究
- 卵巢癌7 項研究
- 胃癌6 項研究
- 食道癌6 項研究
- 癌症（所有類型）6 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。